AstraZeneca PLC (NASDAQ:AZN) Receives $80.00 Average Target Price from Analysts

Shares of AstraZeneca PLC (NASDAQ:AZNGet Free Report) have received a consensus recommendation of “Hold” from the six brokerages that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $80.00.

Several equities analysts have recently issued reports on AZN shares. HSBC started coverage on shares of AstraZeneca in a report on Monday, December 18th. They set a “buy” rating on the stock. Jefferies Financial Group downgraded shares of AstraZeneca from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd. Deutsche Bank Aktiengesellschaft downgraded shares of AstraZeneca from a “hold” rating to a “sell” rating in a report on Thursday, February 8th. Finally, Morgan Stanley assumed coverage on shares of AstraZeneca in a report on Tuesday, January 23rd. They set an “overweight” rating on the stock.

View Our Latest Analysis on AstraZeneca

Institutional Investors Weigh In On AstraZeneca

Large investors have recently bought and sold shares of the company. LPL Financial LLC boosted its position in AstraZeneca by 24.9% in the second quarter. LPL Financial LLC now owns 320,876 shares of the company’s stock valued at $22,965,000 after buying an additional 63,872 shares during the last quarter. Oppenheimer & Co. Inc. boosted its position in AstraZeneca by 51.8% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 14,424 shares of the company’s stock worth $977,000 after purchasing an additional 4,919 shares in the last quarter. Truist Financial Corp boosted its position in AstraZeneca by 2.8% in the 2nd quarter. Truist Financial Corp now owns 247,269 shares of the company’s stock worth $17,697,000 after purchasing an additional 6,741 shares in the last quarter. Barclays PLC boosted its position in AstraZeneca by 317.4% in the 3rd quarter. Barclays PLC now owns 1,242,431 shares of the company’s stock worth $84,136,000 after purchasing an additional 944,765 shares in the last quarter. Finally, 1832 Asset Management L.P. boosted its position in AstraZeneca by 18.9% in the 2nd quarter. 1832 Asset Management L.P. now owns 2,134,805 shares of the company’s stock worth $152,788,000 after purchasing an additional 338,896 shares in the last quarter. Hedge funds and other institutional investors own 15.68% of the company’s stock.

AstraZeneca Stock Performance

Shares of AstraZeneca stock opened at $61.41 on Tuesday. The company has a market capitalization of $190.39 billion, a PE ratio of 31.98, a P/E/G ratio of 1.13 and a beta of 0.52. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.64 and a current ratio of 0.82. The company has a 50-day simple moving average of $66.43 and a two-hundred day simple moving average of $66.65. AstraZeneca has a one year low of $60.47 and a one year high of $76.56.

AstraZeneca (NASDAQ:AZNGet Free Report) last announced its earnings results on Thursday, February 8th. The company reported $0.73 EPS for the quarter, missing analysts’ consensus estimates of $0.74 by ($0.01). The firm had revenue of $12.02 billion during the quarter, compared to the consensus estimate of $12.07 billion. AstraZeneca had a return on equity of 30.19% and a net margin of 13.00%. The business’s revenue for the quarter was up 7.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.69 earnings per share. Research analysts expect that AstraZeneca will post 4.09 EPS for the current fiscal year.

AstraZeneca Increases Dividend

The company also recently announced a Semi-Annual dividend, which will be paid on Monday, March 25th. Investors of record on Friday, February 23rd will be given a $0.965 dividend. The ex-dividend date of this dividend is Thursday, February 22nd. This represents a yield of 2.3%. This is a positive change from AstraZeneca’s previous Semi-Annual dividend of $0.47. AstraZeneca’s dividend payout ratio is currently 47.40%.

About AstraZeneca

(Get Free Report

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Recommended Stories

Analyst Recommendations for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.